Eli Lilly sees FY18 adjusted EPS $5.55-$5.60, consensus $5.58
Sees FY18 revenue $25.3B-$25.8B, consensus $23.43B. At a meeting today with the investment community, Eli Lilly and Company announced its 2019 financial guidance, updated certain elements of its 2018 guidance and 2020 minimum financial expectations, reviewed the performance of recently launched medicines and highlighted numerous potential new medicines in its clinical pipeline. David A. Ricks, Lilly's chairman and chief executive officer, confirmed that the company is executing well against the company's priorities to launch with excellence, replenish the pipeline, improve productivity and develop talent. "Over the past five years, Lilly has successfully launched 10 new medicines, bolstered our pipeline with new candidate medicines from our own labs and from external partners, reshaped the company to be more productive, and attracted world-class scientific talent to our labs," said Ricks. "Our actions over the past several years have positioned Lilly to deliver significant value to our key stakeholders. Most importantly, they have benefited patients, many of whose lives are better because of new Lilly medicines." Ricks acknowledged Lilly's current strong performance, and expressed optimism for the company's future growth. "We are proud of what we have achieved at Lilly over the past several years, but we are determined to raise the bar higher. We see incredible scientific opportunities to address some of the most significant health challenges of an aging society. We aim to create new medicines over the next decade that will transform the care of serious illnesses, and provide valuable new treatment options for doctors and patients."